Toward general prophylactic cancer vaccination

BioEssays

Volumn 31, Issue 10, 2009, Pages 1071-1079

  Hobohm, Uwe ^a  

^a University of Applied Sciences Bioinformatics   (Germany)

Author keywords

Cancer; DC maturation; Fever; Innate immune system; Neoplasm; Oncology; PAMP; Prophylaxis; Regression; Toll ligand; Tumor

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; BCG VACCINE; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; ENDOTOXIN; LYMPHOTOXIN; MELAN A; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2;

ABSENCE OF SIDE EFFECTS; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CD4 CD8 RATIO; CHILL; CROHN DISEASE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ASSOCIATION; FEVER; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; INFECTION; INNATE IMMUNITY; LUNG CANCER; MELANOMA; NONHUMAN;

ANIMALS; BACTERIAL INFECTIONS; CANCER VACCINES; FEMALE; HOT TEMPERATURE; HUMANS; IMMUNITY, INNATE; INFECTION; MALE; NEOPLASMS; SIGNAL TRANSDUCTION; VIRUS DISEASES;

BACTERIA (MICROORGANISMS);

EID: 70349551668     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200900025     Document Type: Article

References (92)

1. Tan, T. T. and Coussens, L. M., Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007. 19: 209-216.
2. Mantovani, A. and Pierotti, M. A., Cancer and inflammation: a complex relationship. Cancer Lett 2008. 267: 180-181.
3. Reinhard, E. H., Good, J. T., and Martin, E., Chemotherapy of malignant neoplastic diseases - abstract of discussion, with statement by MJ Shear, Bethesda. JAMA 1950. 142: 383.
4. Diamond, L. K. and Luhby, L. A., Pattern of 'spontaneous' remissions in leukemia of the childhood, observed in 26 of 300 cases. Am J Med 1951. 10: 238ff.
5. Busch, W., Aus der Sitzung der medicinischen Section vom 13. November 1867. Berliner Klinische Wochenschrift 1868. 5: 137.
6. Rohdenburg, G., Fluctuations in the growth energy of malignant tumors in man, with especial reference to spontaneous recession. J Cancer Res 1918. 3: 193-225.
7. Braunstein, A., Krebs und malaria. Z Krebsforsch 1929. 29: 330-333.
8. Pearl, R., Cancer and tuberculosis. Am J Hyg 1929. 9: 97-162.
9. Hobohm, U., Fever and cancer in perspective. Cancer Immunol Immunother 2001. 50: 391-396.
10. Zahl, P. H., Maehlen, J. and Welch, H. G., The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008. 168: 2311-2316.
11. Ruckdeschel, J. C., Codish, S. D., Stranahan, A. and McKneally, M. F., Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972. 287: 1013-1017.
12. Rotoli, B., Formisano, S., Martinelli, V. and Nigro, M., Long-term survival in acute myelogenous leukemia complicated by chronic active hepatitis. N Engl J Med 1982. 307: 1712-1713.
13. Treon, S. P. and Broitman, S. A., Beneficial effects of post-transfusional hepatitis in acute myelogenous leukemia may be mediated by lipopolysaccharides, tumor necrosis factor alpha and interferon gamma. Leukemia 1992. 6: 1036-1042.
14. Jeys, L. M., Grimer, R. J., Carter, S. R., Tillman, R. M. and Abudu, A., Post-operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol 2007. 14: 2887-2895.
15. Christian, S. and Palmer, L., An apparent recovery from multiple sarcoma with involvement of both bone and soft parts treated by toxin of erysipales and bacillus prodigiosus. Am J Surg 1928. 43: 188-197.
16. Coley-Nauts, H. C., Fowler, G., and Bogatko, F. H., A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand 1953. 145: 5-102.
17. Nauts, H. C. and McLaren, J. R., Coley toxins-the first century. Adv Exp Med Biol 1990. 267: 483-500.
18. Wiemann, B. and Starnes, C. O., Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994. 64: 529-564.
19. Richardson, M. A., Ramirez, T., Russell, N. C. and Moye, L. A., Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med 1999. 5: 42-47.
20. Reilly, H., Microbiology and cancer therapy: a review. Cancer Res 1953. 13: 821-834.
21. Klyuyeva, N. G. and Roskin, G. I., Biotherapy of malignant tumours. Oxford, Pergamon Press, 1963.
22. Grant, R. M., Mackie, R., Cochran, A. J., Murray, E. L., Hoyle, D. and Ross C., Results of administering B.C.G. to patients with melanoma. Lancet 1974. 2: 1096-1100.
23. Mastrangelo, M. J., Sulit, H. L., Prehn, L. M., Bornstein, R. S., Yarbro, J. W. and Prehn, R. T., Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 1976. 37: 684-692.
24. Morton, D. L., Eilber, F. R., Holmes, E. C., Hunt, J. S., Ketcham, A. S., et al. BCG immunotherapy of malignant melanoma: summary of a sevenyear experience. Ann Surg 1974. 180: 635-643.
25. Patard, J., Moudouni, S., Saint, F., Leclercq, N. R., Manunta, A., et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001. 58: 551-556.
26. Low, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999. 17: 37-41.
27. Toso, J. F., Gill, V. J., Hwu, P., Marincola, F. M., Restifo, N. P., et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002. 20: 142-152.
28. Koelmel, K. F., Pfahlberg, A., Mastrangelo, G., Niin, M., Botev, I., et al. Infections and melanoma risk: results of a multicenter EORTC case study. Melanoma Res 1999. 9: 511-519.
29. Kolmel, K. F., Gefeller, O., and Haferkamp, B., Febrile infections and malignant melanoma: results of a case-control study. Melanoma Res 1992. 2: 207-211.
30. Koelmel, K. F., Grange, J. M., Krone, B., Mastrangelo, G., Rossi, C. R., et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 2005. 41: 118-125.
31. Mastrangelo, G., Krone, B., Fadda, E., Buja, A., Grange, J. M., et al. Does yellow fever 17D vaccine protect against melanoma? Vaccine 2009. 27: 588-591.
32. Reif, J., Pearce, N. and Fraser, J., Cancer risks in New Zealand farmers. Int J Epidemiol 1989. 18: 768-774.
33. Rafnsson, V. and Gunnarsdottir, H., Mortality among farmers in Iceland. Int J Epidemiol 1989. 18: 146-151.
34. Wiklund, K. and Steineck, G., Cancer in the respiratory organs of Swedish farmers. Cancer 1988. 61: 1055-1058.
35. Stark, A. D., Chang, H. G., Fitzgerald, E. F., Riccardi, K. and Stone, R. R., A retrospective cohort study of cancer incidence among New York State Farm Bureau members. Arch Environ Health 1990. 45: 155-162.
36. Wang, Y., Lewis-Michl, E. L., Hwang, S. A., Fitzgerald, E. F. and Stark, A. D., Cancer incidence among a cohort of female farm residents in New York State. Arch Environ Health 2002. 57: 561-567.
37. Mastrangelo, G., Grange, J. M., Fadda, E., Fedeli, U., Buja, A. and Lange, J. H., Lung cancer risk: effect of dairy farming and the consequence of removing that occupational exposure. Am J Epidemiol 2005. 161: 1037-1046.
38. Nieuwenhuijsen, M. J., Noderer, K. S., Schenker, M. B., Vallyathan, V. and Olenchock, S., Personal exposure to dust, endotoxin and crystalline silica in California agriculture. Ann Occup Hyg 1999. 43: 35-42.
39. Loeb, L. A., Loeb, K. R. and Anderson, J. P., Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003. 100: 776-781.
40. Trojan, A., Urosevic, M., Dummer, R., Giger, R., Weder, W. and Stahel, R. A., Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer. Lung Cancer 2004. 44: 143-147.
41. Black, M. S., Opler, S. and Speer, S., Structural representations of tumor-host relationships in gastric carcinoma. Surg Gynec Obstet 1956. 102: 599-603.
42. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002. 3: 991-998.
43. Akira, S., Uematsu, S. and Takeuchi, O., Pathogen recognition and innate immunity. Cell 2006. 124: 783-801.
44. Guy, B., The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007. 5: 505-517.
45. Blohm, U., Roth, E., Brommer, K., Dumrese, T., Rosenthal, F. M. and Pircher, H., Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J Immunol 2002. 169: 5522-5530.
46. Gallucci, S., Lolkema, M. and Matzinger, P., Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999. 5: 1249-1255.
47. Alexander, P., Eccles, S. and Gauci, C., The significance of macrophages in human and experimental tumours. Ann N Y Acad Sci 1976. 276: 124-133.
48. Monsurro, V., Wang, E., Yamano, Y., Migueles, S. A., Panelli, M. C., et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004. 104: 1970-1978.
49. Khong, H. T. and Restifo, N. P., Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002. 3: 999-1005.
50. Schuurhuis, D. H., Fu, N., Ossendorp, F. and Melief, C. J. M., Ins and outs of dendritic cells. Int Arch Allergy Immunol 2006. 140: 53-72.
51. Salaun, B., Romero, P. and Lebecque, S., Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 2007. 37: 3311-3318.
52. Letai, A. G., Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008. 8: 121-132.
53. Kurts, C., Sutherland, R. M., Davey, G., Li, M., Lew, A. M., et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 1999. 96: 12703-12707.
54. Melief, C. J., Cancer immunotherapy by dendritic cells. Immunity 2008. 29: 372-383.
55. Trieb, K., Sztankay, A., Amberger, A., Lechner, H. and Grubeck-Loebenstein, B., Hyperthermia inhibits proliferation and stimulates the expression of differentiation markers in cultured thyroid carcinoma cells. Cancer Lett 1994. 87: 65-71.
56. Udono, H. and Srivastava, P. K., Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993. 178: 1391-1396.
57. Multhoff, G., Botzler, C., Wiesnet, M., Müller, E., Meier, T., et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1995. 61: 272-279.
58. Botzler, C., Issels, R. and Multhoff, G., Heat-shock protein 72 cell-surface expression on human lung carcinoma cells is associated with an increased sensitivity to lysis mediated by adherent natural killer cells. Cancer Immunol Immunother 1996. 43: 226-230.
59. Basu, S. and Srivastava, P. K., Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int Immunol 2003. 15: 1053-1061.
60. Shi, H., Cao, T., Connolly, J. E., Monnet, L., Bennett, L., et al. Hyperthermia enhances CTL cross-priming. J Immunol 2006. 176: 2134-2141.
61. Kabelitz, D., Wesch, D. and Oberg, H. H., Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol 2006. 26: 291-306.
62. Yang, Y., Huang, C. T., Huang, X. and Pardoll, D. M., Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004. 5: 508-515.
63. Srivastava, P. K., Therapeutic cancer vaccines. Curr Opin Immunol 2006. 18: 201-205.
64. Maletzki, C., Linnebacher, M., Kreikemeyer, B. and Emmrich, J., Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 2008. 57: 483-491.
65. Linnebacher, M., Maletzki, C., Emmrich, J. and Kreikemeyer, B., Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. J Immunother 2008. 31: 704-713.
66. Matzinger, P., The danger model: a renewed sense of self. Science 2002. 296: 301-305.
67. Kanzler, H., Barrat, F. J., Hessel, E. M. and Coffman, R. L., Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007. 13: 552-559.
68. Wang, B. Z., Quan, F. S., Kang, S. M., Bozja, J., Skountzou, I. and Compans, R. W., Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008. 82: 11813-11823.
69. Hobohm, U., Stanford, J. L. and Grange, J. M., Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol 2008. 28: 95-107.
70. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. and Lanzavecchia, A., Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005. 6: 769-776.
71. Yacyshyn, B. R., Barish, C., Goff, J., Dalke, D., Gaspari, M., et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002. 16: 1761-1770.
72. Bohach, G. A., Fast, D. J., Nelson, R. D. and Schlievert, P. M., Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990. 17: 251-272.
73. Cowdery, J. S., Chace, J. H., Yi, A. K. and Krieg, A. M., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996. 156: 4570-4575.
74. Otto, F., Schmid, P., Mackensen, A., Wehr, U., Seiz, A., et al. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 1996. 32A: 1712-1718.
75. Asprodites, N., Zheng, L., Geng, D., Velasco-Gonzalez, C., Sanchez-Perez, L. and Davila, E., Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J 2008. 22: 3628-3637.
76. Lorenz, E., TLR2 and TLR4 expression during bacterial infections. Curr Pharm Des 2006. 12: 4185-4193.
77. Loof, T. G., Goldmann, O. and Medina, E., Immune recognition of Streptococcus pyogenes by dendritic cells. Infect Immun 2008. 76: 2785-2792.
78. National Cancer Institute Seer cancer statistics review. 2005. http://seer.cancer.gov/csr/1975_2004/result_merged/ topic_historical_mort_trends.pdf
79. Schlehofer, B., Blettner, M., Preston-Martin, S., Niehoff, D., Wahrendorf, J., et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 1999. 82: 155-160.
80. Ma, X., Buffler, P. A., Selvin, S., Matthay, K. K., Wiencke, J. K., et al. Daycare attendance and risk of childhood acute lymphoblastic leukaemia. Br J Cancer 2002. 86: 1419-1424.
81. Perrillat, F., Clavel, J., Auclerc, M. F., Baruchel, A., Leverger, G., et al. Day-care, early common infections and childhood acute leukaemia: a multicentre French case-control study. Br J Cancer 2002. 86: 1064-1069.
82. Deidier, A. Dissertation Medecinal et Chirurgical sur les. Tumeurs, Paris 1725.
83. Braunstein, A., Experimentelle und klinische Grundlagen fuer Malaria-behandlung des Krebses. Z Krebsforsch 1929. 29: 468-490.
84. Sinek, F., Versuch einer statistischen Erfassung endogener Faktoren bei Carcinomerkrankungen. Z Krebsforsch 1936. 44: 492-527.
85. Remy, W., Hammerschmidt, K., Zänker, K. S., Ulm, K., Theisinger, W., et al. Tumorträger haben selten Infekte in der Anamnese. Med Klin 1983. 78: 95-98.
86. Ronne, T., Measles virus infection without rash in childhood is related to disease in adult life. Lancet 1985. 1: 1-5.
87. Grossarth-Maticek, R., Frentzel-Beyme, R., Kanazir, D., Jankovic, M. and Vetter, H., Reported herpes-virus-infection, fever and cancer incidence in a prospective study. J Chronic Dis 1987. 40: 967-976.
88. Abel, U., Becker, N., Angerer, R., Frentzel-Beyme, R., Kaufmann, M., et al. Common infections in the history of cancer patients and controls. J Cancer Res Clin Oncol 1991. 117: 339-344.
89. Devitt, C., Dernell, W., Jameson, V., Lafferty, M., Kuntz, C. and Powers, B., Effect of postoperative infection in dogs with osteosarcoma treated with limb-sparing surgery. Proceedings of the 16th Annual Conference of the Veterinary Cancer Society. 1996. pp. 104-105.
90. Mastrangelo, G., Fadda, E. and Milan, G., Cancer increased after a reduction of infections in the first half of this century in Italy: etiologic and preventive implications. Eur J Epidemiol 1998. 14: 749-754.
91. Grufferman, S., Wang, H. H., DeLong, E. R., Kimm, S. Y., Delzell, E. S. and Falletta, J. M., Environmental factors in the etiology of rhabdomyosarcoma in childhood. J Natl Cancer Inst 1982. 68: 107-113.
92. Hoffmann, C., Rosenberger, A., Troger, W. and Buhring, M., Childhood diseases, infectious diseases, and fever as potential risk factors for cancer? Forsch Komplementarmed Klass Naturheilkd 2002. 9: 324-330.